Industry

CooperVision Completes Enrollment for Clinical Study of Pediatric Myopia Control

Vision Monday5d ago1 min read

ROCHESTER, N.Y.—CooperVision announced it has completed enrollment of its global MiSight 1 day post-approval clinical studies (PAS) in the U.S. and China, described by the company as a milestone in real-world evidence generation for pediatric myopia control. Together, these studies represent the longest international clinical evidence program ever undertaken for soft contact lens-based myopia control intervention in children, according to the company, including both randomized controlled efficacy trials and large-scale safety registries. The combined PAS programs span more than 100 clinical sites and include over 3,000 children.

Read full article on Vision Monday

AI Summary

Quick Take

CooperVision has finalized enrollment for its MiSight 1 day post-approval clinical studies (PAS) in the U.S. and China, marking a major milestone in real-world evidence for myopia management. The program encompasses over 3,000 children across 100 clinical sites, making it the most extensive international clinical evidence program ever conducted for soft contact lens-based myopia intervention.

Why It Matters

While MiSight 1 day is already a cornerstone of myopia control, these post-approval studies are essential for establishing long-term safety and efficacy data across diverse, real-world pediatric populations. As myopia management shifts from a niche specialty to a standard of care, having a massive safety registry helps clinicians address parental concerns regarding contact lens wear in young children with high-level evidence. This initiative reinforces the shift toward data-driven prescribing in an increasingly competitive myopia control market.

Key Details

The program includes both randomized controlled trials and real-world safety registries to provide a comprehensive view of lens performance.
Enrollment was completed simultaneously for both the United States and China study arms.
More than 100 clinical sites are participating in the global data collection effort.
The study is designed to provide the longest-running international evidence for soft contact lens myopia control to date.

Study Snapshot

Design

Randomized controlled efficacy trials and large-scale safety registries

Population

Pediatric patients with myopia

Sample Size

3,000+ children

Practice Implications

The completion of enrollment signals that a significant volume of longitudinal data is forthcoming, which will help clinicians better predict long-term outcomes and safety profiles for daily disposable wear in children. Practitioners should prepare to incorporate these real-world findings into their informed consent process and patient education, particularly for younger children or those in demographics represented in the U.S. and China cohorts.

Who's Affected

Pediatric OptometristsOphthalmologistsContact Lens FittersPractice Owners

What's Next

With enrollment now closed, the studies will move into the long-term monitoring and data collection phase. The industry can expect future updates on safety and efficacy that will likely influence clinical guidelines and the long-term management of pediatric myopia.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.